Similar Search Results

Direct to consumer advertising in pharmaceutical markets

Brekke, Kurt R.; Kuhn, Michael - 2005

We study effects of direct-to-consumer advertising (DTCA) in the prescription drug market. There are two pharmaceutical …

Persistent link: https://www.econbiz.de/10010261296

Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...

Persistent link: https://www.econbiz.de/10013353465

Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2010

We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...

Persistent link: https://www.econbiz.de/10010274913

Margins and market shares: Pharmacy incentives for generic substitution

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2012

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

Persistent link: https://www.econbiz.de/10010291561

Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Persistent link: https://www.econbiz.de/10014080046

Regulation and Pricing of Pharmaceuticals : Reference Pricing or Price Cap Regulation?

Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge - 2021

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10013316907

Advertising Competition in the Free-to-Air TV Broadcasting Industry

Ivaldi, Marc; Zhang, Jiekai - 2017

This paper empirically investigates the advertising competition in the French broadcast television industry within a …, and quantities of advertising of twenty-one TV channels from March 2008 to December 2013. We specify a structural model of … oligopoly competition and identify the shape and magnitude of the feedback loop between TV viewers and advertisers. We also …

Persistent link: https://www.econbiz.de/10011657182

Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry

Anderson, Simon P.; Ciliberto, Federico; Liaukonyte, Jura; … - 2015

We derive equilibrium incentives to use comparative advertising that pushes up own brand perception and pulls down the … matrices identify diversion ratios, from which we derive comparative advertising damage measures. We find that comparative … advertising causes more damage to the targeted rival than benefit to the advertiser. We simulate banning comparative advertising …

Persistent link: https://www.econbiz.de/10011307083

Reference pricing of pharmaceuticals

Brekke, Kurt R.; Koenigbauer, Ingrid; Straume, Odd Rune - 2006

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...

Persistent link: https://www.econbiz.de/10010263999

Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?

Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge - 2007

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10010264178